Search clinical trials for: XG-104

Total 4588 results

Taiho Pharmaceutical Co., Ltd.

Terminated

Phase II Study of TAS-106 to Treat Head and Neck Cancer

Head and Neck Cancer

United States, Hong Kong, Singapore, Taiwan
Hospitech Respiration

Completed

Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System

Ventilator Associated Pneumonia

Romania
Amgen

Terminated

A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy

Cancer | Anemia
Cura Biotech LLC

Unknown

A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis

Osteoarthritis | Rheumatoid Arthritis

United States
Versameb AG
PPD

Not yet recruiting

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence

Stress Urinary Incontinence
Tianjin ConjuStar Biologics Co., Ltd.

Recruiting

Study SC-101 in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Ankyra Therapeutics, Inc

Recruiting

Phase I Study of ANK-101 in Advanced Solid Tumors (ANCHOR)

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Malignant Solid Tumor | Cutaneous Tumor | Subcutaneous Tumor | Metastasis to Soft Tissue

United States, Canada
Betta Pharmaceuticals Co., Ltd.

Recruiting

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Pyxis Oncology, Inc

Recruiting

Study of PYX-106 in Solid Tumors

Solid Tumor

United States, Spain, Belgium
Aardvark Therapeutics, Inc.
Children's Hospital Colorado; Stanford University

Recruiting

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
AnHeart Therapeutics Inc.

Recruiting

Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene

Solid Tumor

China
The University of Hong Kong
Taiho Pharmaceutical Co., Ltd.

Active, not recruiting

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

Pancreas Cancer

Hong Kong
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University

Active, not recruiting

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

Beta-Thalassemia

China
Ultragenyx Pharmaceutical Inc

Active, not recruiting

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

Angelman Syndrome

United States, United Kingdom, Canada, Australia, France, Germany, Spain, Israel
Peptomyc S.L.

Terminated

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure)

Pancreatic Cancer | Advanced Solid Tumors | CRC

Spain
Blue Blood Biotech Corp.

Completed

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

Diabetic Foot Ulcer

Taiwan
Paean Biotechnology Inc.

Completed

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Dermatomyositis | Polymyositis

Korea, Republic of
Avidity Biosciences, Inc.

Enrolling by invitation

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (EXPLORE44OLE)

Duchenne Muscular Dystrophy | DMD | Exon 44 | Duchenne

United States
Agalimmune Ltd.

Completed

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Superficial, Palpable, Unresectable/Metastatic Solid Tumour

United States, Israel, United Kingdom
Fondazione Telethon
Ospedale San Raffaele

Active, not recruiting

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Wiskott-Aldrich Syndrome

Italy, United States
Cellestia Biotech AG

Terminated

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Breast Cancer | Adenoid Cystic Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Osteosarcoma | Non-hodgkin Lymphoma | Glomus Tumor, Malignant | T-ALL

United States, Spain, Korea, Republic of, Germany, France, Switzerland
AstraZeneca

Completed

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

Hypertension

United States
Fervent Pharmaceuticals
ICON plc

Completed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Vasomotor Symptoms | Menopause

United States
Wave Life Sciences Ltd.

Terminated

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

ALS | FTD

Netherlands, United Kingdom
Homology Medicines, Inc

Terminated

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

Phenylketonuria | Phenylketonurias | PAH Deficiency

United States
Hunan Province Tumor Hospital

Completed

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

NSCLC

China
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
Dr. Anupam Sehgal
Taysha Gene Therapies, Inc.; GlycoNet

Active, not recruiting

First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Infantile GM2 Gangliosidosis (Disorder)

Canada
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Invenux, LLC
State University of New York - Downstate Medical Center

Active, not recruiting

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Sickle Cell Disease | Sickle-Beta Zero Thalassemia

United States
Rubius Therapeutics

Terminated

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

Phenylketonurias

United States
LaNova Medicines Limited

Terminated

Study of LM-102 in Subjects in Advanced Tumors

Advanced Solid Tumors

United States
AbbVie

Terminated

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Cancer | Non Small Cell Lung Cancer | Acute Myeloid Leukemia (AML)

United States, France, Israel, Japan, United Kingdom
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

Study of ICP-105 in Solid Tumors Patients

Solid Tumor

China
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
AL-S Pharma

Unknown

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Canada
United BioSource, LLC
AveXis, Inc.

Approved for marketing

AveXis Managed Access Program Cohort for Access to AVXS-101

Spinal Muscular Atrophy

United States
AegisCN LLC
Duke Clinical Research Institute; PharPoint Research, Inc.

Completed

A Proof of Concept Study to Evaluate CN-105 in ICH Patients (CATCH)

Intracerebral Hemorrhage

United States
Cardiora Pty. Ltd.

Completed

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices

Right Heart Failure | Left Ventricular Assist Device

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males

Arrhythmia

Japan
RXi Pharmaceuticals, Corp.

Unknown

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Age-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal Fibrosis

United States
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Cancer

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Healthy Subjects

Ireland
Eisai Co., Ltd.

Completed

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

Solid Tumor

Japan
Protalix

Unknown

Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Israel
Taiho Oncology, Inc.

Approved for marketing

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States
Schiffler Cancer Center

Completed

Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial

Prostatic Neoplasm

United States
Neothetics, Inc

Completed

An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Subcutaneous Adipose Tissue Reduction

United States
Healthpoint

Completed

Cumulative Irritation Potential of 828 Ointment

Healthy Volunteers

United States

Search clinical trials for: XG-104

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations